Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background and Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes. Materials and Methods: Twenty-one patients (three women, 18 men) with type 2 diabetes previously treated with metformin (mean age, 59 yr; body mass index, 28.6 kg/m2; glycosylated hemoglobin, 7.3%) were studied in a two-period crossover design. They received 100 mg V once daily or P for 13 d in randomized order. The incretin effect was measured on d 12 (75-g oral glucose) and d 13 (“isoglycemic” iv glucose) based on insulin and C-peptide determinations and insulin secretion rates (ISR). Results: V relative to P treatment significantly increased intact incretin concentrations after oral glucose and insulin secretory responses to both oral glucose and isoglycemic iv glucose (e.g. AUCISR oral, by 32.7%, P = 0.0006; AUCISR iv, by 33.1%, P = 0.01). The numerical incretin effect was not changed (IEISR, V vs. P, 35.7 ± 4.9 and 34.6 ± 4.0%, P = 0.80). Conclusions: DPP-4 inhibition augmented insulin secretory responses both after oral glucose and during isoglycemic iv glucose infusions, with no net change in the incretin effect. Thus, slight variations in basal incretin levels may be more important than previously thought. Or, DPP-4 inhibitor-induced change in the incretin-related environment of islets may persist overnight, augmenting insulin secretory responses to iv glucose as well. Alternatively, yet unidentified mediators of DPP-4 inhibition may have caused these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“Most likely, GLP-1 interacted with the endocrine pancreas to help release insulin as part of its preserved incretin activity in patients with type 2 diabetes (1, 37).”
BackgroundSelf-citationNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 6×
“without the nutrient-stimulated release of incretin hormones, and it could be speculated that this may lead to an at least partial restoration of the reduced incretin effect (9).”
BackgroundMethodResultSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Nevertheless, this can be overcome by stimulating insulin secretion with exogenous GLP-1 (10, 14).”
BackgroundSelf-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 2×
“glucose concentrations after both loads are comparable (“isoglycemia”) (8, 9).”
BackgroundMethodSelf-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Self-citationThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“It is an open question whether GIP has made a significant contribution to this process because GIP is hardly insulinotropic in hyperglycemic patients with type 2 diabetes (10, 38).”
BackgroundPrehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363
Polonsky, K. S., Licinio-Paixao, J., Given, B. D., Pugh, W., Rue, P., Galloway, J., Karrison, T., & Frank, B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112308 · Cited by 359
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Self-citationNauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · cited 1×
“Because incretin hormones usually have low, basal concentrations in the fasting state and rapidly increase after nutrient ingestion (4, 6), DPP-4 inhibition supposedly has primarilypostprandial effects,withsomeadditionalglucoseloweringeffect in the fastingstate, and is therefore thought to act as an “incretin enhancer…”
BackgroundSelf-citationEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
Tillil, H., Shapiro, E. T., Miller, M. A., Karrison, T., Frank, B. H., Galloway, J. A., Rubenstein, A. H., & Polonsky, K. S. (1988) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1988.254.3.e349 · Cited by 105 · cited 1×
“even if the same amount of glucose is given (7) or the”
BackgroundD'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99 · cited 1×
“Because incretin hormones usually have low, basal concentrations in the fasting state and rapidly increase after nutrient ingestion (4, 6), DPP-4 inhibition supposedly has primarilypostprandial effects,withsomeadditionalglucoseloweringeffect in the fastingstate, and is therefore thought to act as an “incretin enhancer…”
BackgroundSelf-citationHøjberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89
Self-citationHøjberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56 · cited 1×
“The ability of GIP to augment insulin secretion could only partly be rescued by intensive diabetes treatment aiming at near-normal glucose control in such patients (39, 40).”
BackgroundSelf-citation
Cited by
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Self-citationMeier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Self-citationIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Data from (a, g) Nauck et al [2] (oral glucose load 50 g); (b, h) Knop et al [71] (oral glucose load 75 g); (c, i) Bagger et al [3] (oral glucose loads of 25, 75 and 125 g); (d, j) Vardarli et al [72] (oral glucose load 75 g; after placebo and vildagliptin treatment); (e, k) Vardarli et al 2014 [73] (oral glucose load…”
BackgroundMethodInfluentialSelf-citationEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationFoley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83
“It has recently been reported that, following vildagliptin treatment for 12 days, insulin secretion was increased during a morning intravenous glucose challenge after an overnight fast [13]; the effects on capacity seen in the current study could thus be due to increased basal GLP-1 and GIP.”
BackgroundSelf-citation
Metadata
- Authors
- Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-04-01
- Volume
- 96
- Issue
- 4
- Pages
- 945-954
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2006612490
- Cited by
- 61
- References
- 19
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.